Evidence map›Paper›PMID 29258679›Full record

ReviewEuropean urology2018

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Jun Luo, Gerhardt Attard, Steven P Balk, Charlotte Bevan, Kerry Burnstein, Laura Cato, Artem Cherkasov, Johann S De Bono, Yan Dong, Allen C Gao and 17 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 6 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 6 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Contemporary review of prognostic markers of prostate cancer from a pathologist perspective.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2025
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 20 institutions in 5 countries.

Jun LuoDepartment of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA. Electronic address: jluo1@jhmi.edu.
Gerhardt AttardThe Institute of Cancer Research, London, UK.
Steven P BalkHematology-Oncology Division, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Charlotte BevanDepartment of Surgery & Cancer, Imperial College London, Imperial Centre for Translational & Experimental Medicine (ICTEM), Hammersmith Hospital Campus, London, UK.
Kerry BurnsteinDepartment of Molecular & Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA.
Laura CatoDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Artem CherkasovDepartment of Urologic Sciences, University of British Columbia, The Vancouver Prostate Centre, Vancouver, BC, Canada.
Johann S De BonoDivision of Clinical Studies, The Institute of Cancer Research, London, UK.
Yan DongDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, USA.
Allen C GaoDepartment of Urology, University of California Davis, Sacramento, CA, USA.
Martin GleaveDepartment of Urologic Sciences, University of British Columbia, The Vancouver Prostate Centre, Vancouver, BC, Canada.
Hannelore HeemersDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Urology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Hematology/Medical Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Mayuko KanayamaDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Ralf KittlerMcDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, TX, USA.
Joshua M LangDepartment of Medicine, Carbone Cancer Center, University of Wisconsin, Madison, WI, USA.
Richard J LeeDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Christopher J LogothetisDivision of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert MatusikDepartment of Urologic Surgery, Vanderbilt Prostate Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Stephen PlymateDepartment of Medicine, University of Washington and VAPSHCS GRECC, Seattle, WA, USA.
Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Luke A SelthDame Roma Mitchell Cancer Research Laboratories and Freemasons Foundation Centre for Men's Health, Adelaide Medical School, The University of Adelaide, SA, Australia.
Howard SouleProstate Cancer Foundation, Santa Monica, CA, USA.
Wayne TilleyDame Roma Mitchell Cancer Research Laboratories and Freemasons Foundation Centre for Men's Health, Adelaide Medical School, The University of Adelaide, SA, Australia.
Nancy L WeigelDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Amina ZoubeidiDepartment of Urologic Sciences, University of British Columbia, The Vancouver Prostate Centre, Vancouver, BC, Canada.
Scott M DehmMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA; Department of Urology, University of Minnesota, Minneapolis, MN, USA. Electronic address: dehm@umn.edu.
Ganesh V RajDepartment of Urology, UT Southwestern Medical Center at Dallas, Dallas, TX, USA; Department of Urology and Pharmacology, UT Southwestern Medical Center at Dallas, Dallas, TX, USA. Electronic address: ganesh.raj@utsouthwestern.edu.
University of British Columbia · CAFreemasons Foundation Centre for Men's Health · AUInstitute of Cancer Research · GBBaylor College of Medicine · USBeth Israel Deaconess Medical Center · USCleveland Clinic Lerner College of Medicine · USHarvard University · USImperial College London · GBJohns Hopkins University · USJuntendo University · JPMassachusetts General Hospital · USMemorial Sloan Kettering Cancer Center · USProstate Cancer Foundation · USSouthwestern Medical Center · USThe University of Texas MD Anderson Cancer Center · USTulane University · USUniversity of California, Davis · USUniversity of Miami · USUniversity of Washington · USUniversity of Wisconsin Carbone Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0M
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8M
Understanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8M
Towards selective androgen deprivation by targeting androgen activation of SRFR01CA166440 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HEEMERS, HANNELORE · 2014 to 2024
$3.4M
Defining Melanoma Therapeutic Avenues by Integrative Functional GenomicsDP2OD002750 · OD · DANA-FARBER CANCER INST · PI GARRAWAY, LEVI ALEXANDER · 2007 to 2007
$2.6M
An inevitable mechanism of resistance to androgen-directed therapyR01CA188609 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI DONG, YAN · 2014 to 2018
$1.6M
Vav3 Oncogene Potentiation of Androgen Receptor Signaling in Prostate Cancer.R01CA132200 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BURNSTEIN, KERRY L · 2009 to 2013
$1.6M
The aberrant androgen receptor underlies abiraterone/enzalutamide resistanceR01CA185297 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANTONARAKIS, EMMANUEL S., LUO, JUN · 2015 to 2018
$1.5M
Targeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate CancerI01BX003324 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI PLYMATE, STEPHEN R. · 2016 to 2024
–
BLRD VA I01 BX003324NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA132200NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA166440NCI NIH HHS R01 CA185297NCI NIH HHS R01 CA188609NCI NIH HHS U54 CA224079NIH HHS DP2 OD002750Prostate Cancer UK CEO13_2-002
6 · The paper itself

Abstract

contextAlthough a number of studies have demonstrated the importance of constitutively active androgen receptor variants (AR-Vs) in prostate cancer, questions still remain about the precise role of AR-Vs in the progression of castration-resistant prostate cancer (CRPC).

objectiveKey stakeholders and opinion leaders in prostate cancer convened on May 11, 2017 in Boston to establish the current state of the field of AR-Vs. EVIDENCE ACQUISITION: The meeting "Mission Androgen Receptor Variants" was the second of its kind sponsored by the Prostate Cancer Foundation (PCF). This invitation-only event was attended by international leaders in the field and representatives from sponsoring organizations (PCF and industry sponsors). Eighteen faculty members gave short presentations, which were followed by in-depth discussions. Discussions focused on three thematic topics: (1) potential of AR-Vs as biomarkers of therapeutic resistance; (2) role of AR-Vs as functionally active CRPC progression drivers; and (3) utility of AR-Vs as therapeutic targets in CRPC. EVIDENCE SYNTHESIS: The three meeting organizers synthesized this meeting report, which is intended to summarize major data discussed at the meeting and identify key questions as well as strategies for addressing these questions. There was a critical consensus that further study of the AR-Vs is an important research focus in CRPC. Contrasting views and emphasis, each supported by data, were presented at the meeting, discussed among the participants, and synthesized in this report.

conclusionsThis article highlights the state of knowledge and outlines the most pressing questions that need to be addressed to advance the AR-V field. PATIENT SUMMARY: Although further investigation is needed to delineate the role of androgen receptor (AR) variants in metastatic castration-resistant prostate cancer, advances in measurement science have enabled development of blood-based tests for treatment selection. Detection of AR variants (eg, AR-V7) identified a patient population with poor outcomes to existing AR-targeting therapies, highlighting the need for novel therapeutic agents currently under development.

Indexed as

AgedAndrogen AntagonistsAndrostenesBenzamidesBiomarkers, TumorCongresses as TopicDisease-Free SurvivalFollow-Up StudiesHumansMaleMiddle AgedNitrilesPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantReceptors, AndrogenRisk AssessmentabirateroneAndrogen AntagonistsAndrostenesBenzamidesBiomarkers, TumorenzalutamideNitrilesPhenylthiohydantoinReceptors, AndrogenAbirateroneAndrogen receptor variant 7Androgen receptor variantsCastration-resistant prostate cancerEnzalutamide

Identifiers

PMID29258679
PMCPMC5929166
OpenAlexW2774748297

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.